Floatz logo

TRASTUZUMAB

Urinary Bladder Carcinoma

NKGen Biotech, Inc.monoclonal_antibodyPhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

120 Active assets in the Urinary Bladder Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
Vinblastine
University of Southern California
Phase 3BB
Pembrolizumab
Essen Biotech
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
inflammatory breast carcinomaActive
BBB
Indicative · Phase 3
74 / 100
View asset →
HER2 positive breast carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →